Study on Niraparib and Dostarlimab for Patients with HPV-Negative Head and Neck Squamous Cell Carcinoma

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). The study will use a combination of two treatments: Niraparib, which is a medication taken as a tablet, and Dostarlimab, which is given through an infusion into a vein. Niraparib is also known by its code name MK-4827, and Dostarlimab is sometimes referred to as TSR-042.

The purpose of the study is to evaluate how effective this combination of treatments is for patients with HNSCC. Participants in the study will receive these treatments over a period of time, and their progress will be monitored. The study will include an initial phase where the safety of the treatments is assessed, followed by a longer period where the effectiveness of the treatments is evaluated. This will involve regular check-ups and possibly imaging tests like MRI to see how the cancer responds to the treatment.

Throughout the study, the safety of the treatments will be closely monitored, especially after surgery, to ensure that any side effects are managed. The study will also look at how the cancer responds to the treatments and whether there are any changes in the cancer’s genetic makeup. The goal is to understand better how these treatments can help manage HNSCC and improve outcomes for patients with this type of cancer.

1 induction phase

During the induction phase, the patient will receive a combination of medications to prepare for further treatment. This phase involves the administration of niraparib and dostarlimab.

Niraparib is provided in the form of 100 mg film-coated tablets, taken orally. The specific dosage and frequency will be determined by the healthcare provider based on individual patient needs.

Dostarlimab is administered as a 500 mg concentrate for solution, given through an intravenous infusion. The frequency and duration of this treatment will also be specified by the healthcare provider.

2 surgery

Following the induction phase, the patient will undergo surgery. The goal of the surgery is to remove the tumor and assess the response to the induction treatment.

The surgical procedure will be evaluated for safety, focusing on potential complications such as bleeding, wound healing issues, infection, and the need for additional surgical interventions.

3 maintenance phase

After surgery, the patient will enter the maintenance phase. This phase aims to prevent cancer recurrence and involves continued treatment with niraparib.

Niraparib will be administered as 100 mg film-coated tablets, taken orally. The healthcare provider will determine the appropriate dosage and duration of this treatment.

4 follow-up and monitoring

Throughout the trial, the patient’s health and response to treatment will be closely monitored. This includes regular medical assessments and imaging tests to evaluate the effectiveness of the treatment and detect any signs of cancer recurrence.

The follow-up period will extend for a specified duration after the completion of the maintenance phase, ensuring comprehensive monitoring of the patient’s condition.

Who Can Join the Study?

The patient must have a type of cancer called squamous cell carcinoma in specific areas like the mouth, throat, or voice box, and it should be possible to remove it with surgery aimed at curing the disease.
For throat cancer, the cancer must be HPV-negative, which means it is not caused by the human papillomavirus. This is checked using a special test.
The cancer must be at a specific stage, known as stage III-IV(M0), which means it is advanced but has not spread to distant parts of the body. The patient should not have cancer that has come back or spread after previous treatments.
The patient must have a good general health status, known as performance status ECOG 0-1, which means they are fully active or have some symptoms but can still carry out light work.
The patient should not have another type of cancer, except for certain types that are not serious or have been completely treated at least two years ago.
The patient must have normal functioning of important organs and blood cells, which includes specific levels of blood components and kidney and liver function.
The patient must be able to swallow the medication used in the study.
The patient must agree not to donate blood during the study and for 90 days after the last dose of the study treatment.
If the patient is a woman who can have children, she must have a negative pregnancy test before starting the study and agree to use effective birth control during the study and for 180 days after the last dose. If she cannot have children, she must meet certain criteria, such as being of a certain age and not having periods for over a year, or having had surgery to remove reproductive organs.
The patient must agree not to breastfeed during the study and for 120 days after the last dose of the study treatment.
If the patient is a man, he must agree to use effective birth control during the study and for 180 days after the last dose. Abstinence is acceptable if it is the chosen method of contraception.

Who Cannot Join the Study?

Patients with HPV-positive Head and Neck Squamous Cell Carcinoma (HNSCC) cannot participate. HPV stands for Human Papillomavirus, a virus that can affect the skin and the moist membranes lining your body.
Patients who are not within the specified age range for the study cannot participate. The age range is typically defined by the study organizers.
Patients who are not part of the specified clinical trial groups cannot participate. Clinical trial groups are categories of patients that the study is focusing on.
Patients who are part of a vulnerable population may not be eligible. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
IRCCS Humanitas Research Hospital	Rozzano	Italy

Other Sites

Site Name	City	Country
Istituto Oncologico Veneto	Padua	Italy
Pia Fondazione Di Culto E Religione Card G Panico	Tricase	Italy
IRCCS Ospedale Policlinico San Martino	Genoa	Italy
Azienda Ospedaliero-Universitaria Maggiore Della Carita	Novara	Italy
Universita Degli Studi Di Brescia	Brescia	Italy
Izoshv Iylwcumq Fdngjzhwlzyhd Oofkzjhsmhk	Rome	Italy
Uireauaild Dcmnj Sfgic Di Rfkc Lk Shmlqgmv	Rome	Italy

Trial status

Country	Status	Recruitment Start
Italy	Recruiting	08.02.2021

Trial locations

Investigated drugs:

PARP Inhibitor is a type of medication that blocks an enzyme used by cells to repair damage to their DNA. In this trial, it is used to see if it can help treat head and neck squamous cell carcinoma by preventing cancer cells from repairing themselves, which may lead to their death.

Immunotherapy is a treatment that uses the body’s own immune system to fight cancer. It helps the immune system recognize and attack cancer cells more effectively. In this trial, immunotherapy is combined with the PARP inhibitor to see if the combination is more effective in treating head and neck squamous cell carcinoma.

Investigated diseases:

Oropharyngeal squamous cell carcinoma

HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) – This is a type of cancer that occurs in the squamous cells lining the head and neck region, excluding those associated with the human papillomavirus (HPV). It typically begins in the mucous membranes of the mouth, nose, or throat. The disease progresses as the cancer cells grow and form tumors, which can invade nearby tissues and spread to other parts of the body. Symptoms may include a persistent sore throat, difficulty swallowing, and changes in voice. As the disease advances, it can lead to more severe symptoms and complications. Early detection and monitoring are crucial for managing the progression of this cancer.

Trial ID:

2024-516798-54-00

NCT ID:

NCT04681469

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Niraparib and Dostarlimab for Patients with HPV-Negative Head and Neck Squamous Cell Carcinoma

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?